Atomi Financial Group Inc. raised its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,146 shares of the company’s stock after buying an additional 1,473 shares during the period. Atomi Financial Group Inc.’s holdings in Novo Nordisk A/S were worth $2,765,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Natixis Advisors LLC raised its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC grew its position in Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Talbot Financial LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $4,066,000. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $86,000. Finally, Zions Bancorporation N.A. boosted its stake in shares of Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Stock Performance
NYSE:NVO opened at $78.74 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm’s fifty day simple moving average is $97.15 and its 200 day simple moving average is $116.47. The stock has a market cap of $353.33 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on Novo Nordisk A/S
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
- Five stocks we like better than Novo Nordisk A/S
- Top Biotech Stocks: Exploring Innovation Opportunities
- Tesla Cybertruck Discounts: What They Mean for the Stock Price
- Investing In Automotive Stocks
- Intuitive Surgical Leads the Pack in Robotic Surgery Innovation
- What Are Dividend Achievers? An Introduction
- Transports Are Trending Higher: It’s a Golden Time to Buy More
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.